Cargando…
Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer
Background: Stromelysins are potential breast cancer biomarkers. The aim of the study was to evaluate if plasma levels of selected metalloproteinases (MMPs) (stromelysin-1 (MMP-3) and stromelysin-10 (MMP-10)) and cancer antigen 15-3 (CA 15-3) used separately and in combination demonstrated diagnosti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767367/ https://www.ncbi.nlm.nih.gov/pubmed/33371324 http://dx.doi.org/10.3390/jcm9124122 |
_version_ | 1783628942009171968 |
---|---|
author | Piskór, Barbara Maria Przylipiak, Andrzej Dąbrowska, Emilia Sidorkiewicz, Iwona Niczyporuk, Marek Szmitkowski, Maciej Ławicki, Sławomir |
author_facet | Piskór, Barbara Maria Przylipiak, Andrzej Dąbrowska, Emilia Sidorkiewicz, Iwona Niczyporuk, Marek Szmitkowski, Maciej Ławicki, Sławomir |
author_sort | Piskór, Barbara Maria |
collection | PubMed |
description | Background: Stromelysins are potential breast cancer biomarkers. The aim of the study was to evaluate if plasma levels of selected metalloproteinases (MMPs) (stromelysin-1 (MMP-3) and stromelysin-10 (MMP-10)) and cancer antigen 15-3 (CA 15-3) used separately and in combination demonstrated diagnostic usefulness in breast cancer (BC). Methods: The study group consisted of 120 patients with BC, while the control group included 40 patients with benign breast cancer and 40 healthy individuals. Concentrations of MMP-3 and MMP-10 were determined by enzyme-linked immunosorbent assay; CA 15-3 was determined by chemiluminescent microparticle immunoassay. Results: In the group of patients with BC, the area under the curve (AUC) was significantly higher for all markers (except MMP-3) and all sets of markers. At the earliest disease stage, only MMP-10 had a significantly higher AUC (AUC = 0.8692, p < 0.001). Moreover, MMP-10 had the highest AUC (0.9166) among parameters tested separately. The highest AUC was observed for the combination of MMP-10 + CA 15-3 and MMP-3 + MMP-10 + CA 15-3 in line with disease progression (stage I 0.8884 and 0.8906, stage II 0.9244 and 0.9308, stages III + IV 0.9919 and 0.9944, respectively, p < 0.001 in all cases). Conclusions: The results suggest that MMP-10 could be a potential marker in early stages of BC. Moreover, plasma concentration of MMP-10 and MMP-3 in combination with CA 15-3 may improve diagnosis of this type of cancer. |
format | Online Article Text |
id | pubmed-7767367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77673672020-12-28 Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer Piskór, Barbara Maria Przylipiak, Andrzej Dąbrowska, Emilia Sidorkiewicz, Iwona Niczyporuk, Marek Szmitkowski, Maciej Ławicki, Sławomir J Clin Med Article Background: Stromelysins are potential breast cancer biomarkers. The aim of the study was to evaluate if plasma levels of selected metalloproteinases (MMPs) (stromelysin-1 (MMP-3) and stromelysin-10 (MMP-10)) and cancer antigen 15-3 (CA 15-3) used separately and in combination demonstrated diagnostic usefulness in breast cancer (BC). Methods: The study group consisted of 120 patients with BC, while the control group included 40 patients with benign breast cancer and 40 healthy individuals. Concentrations of MMP-3 and MMP-10 were determined by enzyme-linked immunosorbent assay; CA 15-3 was determined by chemiluminescent microparticle immunoassay. Results: In the group of patients with BC, the area under the curve (AUC) was significantly higher for all markers (except MMP-3) and all sets of markers. At the earliest disease stage, only MMP-10 had a significantly higher AUC (AUC = 0.8692, p < 0.001). Moreover, MMP-10 had the highest AUC (0.9166) among parameters tested separately. The highest AUC was observed for the combination of MMP-10 + CA 15-3 and MMP-3 + MMP-10 + CA 15-3 in line with disease progression (stage I 0.8884 and 0.8906, stage II 0.9244 and 0.9308, stages III + IV 0.9919 and 0.9944, respectively, p < 0.001 in all cases). Conclusions: The results suggest that MMP-10 could be a potential marker in early stages of BC. Moreover, plasma concentration of MMP-10 and MMP-3 in combination with CA 15-3 may improve diagnosis of this type of cancer. MDPI 2020-12-21 /pmc/articles/PMC7767367/ /pubmed/33371324 http://dx.doi.org/10.3390/jcm9124122 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Piskór, Barbara Maria Przylipiak, Andrzej Dąbrowska, Emilia Sidorkiewicz, Iwona Niczyporuk, Marek Szmitkowski, Maciej Ławicki, Sławomir Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer |
title | Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer |
title_full | Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer |
title_fullStr | Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer |
title_full_unstemmed | Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer |
title_short | Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer |
title_sort | plasma level of mmp-10 may be a prognostic marker in early stages of breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767367/ https://www.ncbi.nlm.nih.gov/pubmed/33371324 http://dx.doi.org/10.3390/jcm9124122 |
work_keys_str_mv | AT piskorbarbaramaria plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer AT przylipiakandrzej plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer AT dabrowskaemilia plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer AT sidorkiewicziwona plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer AT niczyporukmarek plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer AT szmitkowskimaciej plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer AT ławickisławomir plasmalevelofmmp10maybeaprognosticmarkerinearlystagesofbreastcancer |